摘要
Metabolic-associated steatotic liver disease(MASLD),formerly referred to as non-alcoholic fatty liver disease,represents an escalating worldwide medical burden defined by hepatic steatosis,inflammation,fibrosis,and potential progression to cirrhosis or hepatocellular carcinoma.Artificial intelligence(AI)has emerged as a transformative tool in MASLD management,enhancing diagnostic accuracy,risk stratification,and treatment optimization.This review explores the integration of AI in MASLD diagnosis,including AI-based histopathological assessment,non-invasive screening models,imaging diagnostics,and gut microbiota-based app-roaches.Additionally,AI-driven treatment strategies facilitate personalized management,assess therapeutic response,and contribute to drug discovery.Despite its advantages,challenges such as data integration,model interpretability,and cost-effectiveness remain obstacles to widespread adoption.Future advan-cements in explainable AI,multi-modal data fusion,and cost-efficient implement-ations will be crucial for maximizing AI’s impact on MASLD care.AI-driven innovations hold great promise for improving early detection,guiding person-alized treatment,and ultimately enhancing patient outcomes in MASLD.
